Emergent BioSolutions Lowers FY2026 Sales Guidance from $645.000M-$675.000M to $600.000M-$645.000M vs $657.133M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $645.000 million-$675.000 million to $600.000 million-$645.000 million vs $657.133 million estimate.
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $645.000 million-$675.000 million to $600.000 million-$645.000 million vs $657.133 million estimate.